吉非替尼对比多西紫杉醇治疗非小细胞肺癌的Meta分析  

Meta analysis of gefitinib and docetaxel for non-small cell lung cancer( NSCLC)

作　　者：魏素文[1] 戴晓倩[1] 马丽[1] 付晓燕[1] 

机构地区：[1]兰州大学第一医院急诊科,甘肃兰州730000

出　　处：《现代肿瘤医学》2014年第7期1581-1586,共6页Journal of Modern Oncology

摘　　要：目的:系统评价吉非替尼与多西紫杉醇二者治疗非小细胞肺癌的有效性和安全性。方法:计算机检索Cochrane图书馆(建库至2013年第8期)、PubMed、Embase、CNKI、维普及万方数据库(截至2013年9月),同质研究采用RevMan 5.0软件进行合并分析。采用Cochrane Reviewer's handbook 5.1.0进行质量评价。结果:共纳入9个随机对照试验,包括2179例患者。与多西紫杉醇相比,吉非替尼能够提高总有效率[RR=1.40,95%CI(1.12,1.74)]和TOI改善率[RR=1.85,95%CI(1.49,2.31)],降低中性粒细胞减少发生率[RR=0.23,95%CI(0.11,0.49)]。结论:与多西紫杉醇相比,吉非替尼显示出更多的优势;尚需更多高质量的研究证明其有效性和安全性。Objective： To evaluate the clinical efficacy and safety of gefitinib and docetaxel for NSCLC. Methods： The Cochrane Library （ Issue 8,2013 ）, PubMed, Embase, CNKI, VIP, and Wanfang database were searched （ up to September 2013 ）. Meta -analyses were performed by RevMan 5.0 software, and quatility assessment was carried out with Cochrane Reviewerg handbook 5.1.0. Results：9 randomized controlled trials （RCTs） involving 2179 patients were included in this meta analysis. The results of meta- analyses showed that ： compared to docetaxel, gefitinib could improve over response rate[ RR = 1.40,95% CI（1.12,1. 74） ] and TOIl RR = 1.85,95% CI（ 1.49,2.31 ） ] with lower hematology toxicity rate. Conclusion：Gefitinib shows more superiority for NSCLC compared to docetaxel. High quality RCTs and economic evaluation are needed.

关 键 词：吉非替尼 多西紫杉醇 非小细胞肺癌 META分析 

分 类 号：R734.2[医药卫生—肿瘤]